EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways

Qian Zhang, Zhongfan Zhang, Weiwei Chen, Haikuo Zheng, Daoyuan Si, Wenqi Zhang

PeerJ · 2023

DOI: 10.7717/peerj.16097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Qian Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China. Hauptthemen laut MEDLINE: Rivaroxaban, Myocardial Infarction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific and Technological Developing Scheme of Ji Lin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Factor Xa (FXa) not only plays an active role in the coagulation cascade but also exerts non-hemostatic signaling through the protease-activated receptors (PARs). This study aimed to investigate whether the FXa inhibitor, Rivaroxaban (RIV), attenuates adverse cardiac remodeling in rats with myocardial infarction (MI) and to identify the underlying molecular mechanisms it uses.

Methods

An MI model was induced in eight-week-old, male Wistar rats, by permanent ligation of the left anterior descending coronary artery. MI rats were randomly assigned to receive RIV or protease-activated receptors 2-antagonist (PAR-2 antagonist, FSLLRY) treatment for four weeks. Histological staining, echocardiography and hemodynamics were used to assess the cardioprotective effects of RIV. Meanwhile, pharmacological approaches of agonist and inhibitor were used to observe the potential pathways in which RIV exerts antifibrotic effects in neonatal rat cardiac fibroblasts (CFs). In addition, real-time PCR and western blot analysis were performed to examine the associated signaling pathways.

Results

RIV presented favorable protection of left ventricular (LV) cardiac function in MI rats by significantly reducing myocardial infarct size, ameliorating myocardial pathological damage and improving left ventricular (LV) remodeling. Similar improvements in the PAR-2 antagonist FSLLRY and RIV groups suggested that RIV protects against cardiac dysfunction in MI rats by ameliorating PAR-2 activation. Furthermore, an in vitro model of fibrosis was then generated by applying angiotensin II (Ang II) to neonatal rat cardiac fibroblasts (CFs). Consistent with the findings of the animal experiments, RIV and FSLLRY inhibited the expression of fibrosis markers and suppressed the intracellular upregulation of transforming growth factor β1 (TGFβ1), as well as its downstream Smad2/3 phosphorylation effectors in Ang II-induced fibrosis, and PAR-2 agonist peptide (PAR-2 AP) reversed the inhibition effect of RIV.

Conclusions

Our findings demonstrate that RIV attenuates MI-induced cardiac remodeling and improves heart function, partly by inhibiting the activation of the PAR-2 and TGF-β1 signaling pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RivaroxabanMyocardial InfarctionRatsAnimalsMaleTransforming Growth Factor beta1Factor XaVentricular RemodelingRats, WistarSignal TransductionFibrosisReceptors, Proteinase-Activated

Stichwörter der Autor:innen

Adverse cardiac remodelingCoagulation factor XaProtease-activated receptors-2RivaroxabanTransforming growth factor β1 (TGFβ1)

Substanzen

RivaroxabanTransforming Growth Factor beta1Factor XaReceptors, Proteinase-Activated

Autor:innen und Institutionen

  • Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.

Förderung

  • The Scientific and Technological Developing Scheme of Ji Lin Province

Zitieren

APA

Zhang, Q., Zhang, Z., Chen, W., Zheng, H., Si, D., & Zhang, W. (2023). Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways. PeerJ. https://doi.org/10.7717/peerj.16097

Vancouver

Zhang Q, Zhang Z, Chen W, Zheng H, Si D, Zhang W. Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways. PeerJ. 2023. doi:10.7717/peerj.16097

BibTeX
@article{Zhang2023,
  author = {Zhang, Qian and Zhang, Zhongfan and Chen, Weiwei and Zheng, Haikuo and Si, Daoyuan and Zhang, Wenqi},
  title = {Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.16097}
}
Kostenlos starten →